UBS Group Has Lowered Expectations for Stevanato Group (NYSE:STVN) Stock Price

Stevanato Group (NYSE:STVN) had its price objective decreased by analysts at UBS Group from $24.00 to $23.50 in a research report issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock.

Several other equities analysts have also issued reports on the company. Bank of America boosted their price objective on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Morgan Stanley reiterated an “equal weight” rating and issued a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Finally, Wolfe Research began coverage on shares of Stevanato Group in a report on Friday, December 13th. They set an “outperform” rating and a $28.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of €27.75 ($29.84).

Stevanato Group Stock Performance

Stevanato Group stock traded up €0.25 ($0.27) during trading hours on Friday, reaching €20.95 ($22.53). 54,974 shares of the company were exchanged, compared to its average volume of 333,614. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The stock has a 50-day moving average of €21.38 and a 200 day moving average of €20.52. The firm has a market cap of $6.34 billion, a price-to-earnings ratio of 44.57, a PEG ratio of 7.18 and a beta of 0.56. Stevanato Group has a 12 month low of €16.56 ($17.81) and a 12 month high of €33.49 ($36.01).

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The firm had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. As a group, research analysts anticipate that Stevanato Group will post 0.5 earnings per share for the current year.

Institutional Trading of Stevanato Group

Several hedge funds and other institutional investors have recently modified their holdings of STVN. Conestoga Capital Advisors LLC boosted its position in shares of Stevanato Group by 5.3% during the 4th quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company’s stock worth $176,128,000 after purchasing an additional 407,086 shares in the last quarter. TimesSquare Capital Management LLC boosted its holdings in Stevanato Group by 114.6% in the fourth quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company’s stock worth $71,657,000 after acquiring an additional 1,756,100 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in Stevanato Group by 67.6% in the third quarter. Thrivent Financial for Lutherans now owns 2,784,912 shares of the company’s stock valued at $55,698,000 after acquiring an additional 1,123,104 shares during the period. Wellington Management Group LLP increased its holdings in shares of Stevanato Group by 4.5% during the third quarter. Wellington Management Group LLP now owns 2,693,588 shares of the company’s stock valued at $53,872,000 after acquiring an additional 115,050 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in shares of Stevanato Group by 28.7% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company’s stock valued at $51,333,000 after acquiring an additional 524,989 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.